Akums Drugs and Pharmaceuticals, one of India’s leading contract development and manufacturing organizations (CDMO), has unveiled its new dual-action heartburn relief chewable tablets. The innovative formulation, combining Famotidine, Calcium Carbonate, and Magnesium Hydroxide, is designed to offer both immediate and sustained relief for individuals suffering from gastroesophageal reflux disease (GERD) and related symptoms.

The newly launched chewable tablets mark a significant advancement in the treatment of heartburn by pairing an antacid, which provides rapid neutralization of stomach acid, with Famotidine, a histamine H2-receptor antagonist that suppresses acid production for extended relief. This combination aims to set a new benchmark in pharmaceutical excellence by ensuring quick and long-lasting symptom relief for patients.

Sanjeev Jain, Managing Director of Akums Drugs and Pharmaceuticals, expressed enthusiasm about the launch. "Heartburn is a common issue that affects millions of people. At Akums, we are committed to developing effective and innovative healthcare solutions. Our dual-action chewable tablet is a breakthrough product, providing fast, safe, and sustained relief from heartburn symptoms."

Targeting a Growing Health Concern

Heartburn, characterized by a burning sensation in the chest due to gastric acid refluxing into the esophagus, is a widespread problem in India. Akums’ chewable tablets address this issue by combining the immediate acid-neutralizing effects of Calcium Carbonate and Magnesium Hydroxide with the prolonged acid-suppressing action of Famotidine, offering comprehensive relief and preventing recurrence of symptoms.

According to Sandeep Jain, Managing Director of Akums, the product meets a growing demand in the Indian market. "With the increasing prevalence of GERD and similar conditions, there is a clear need for treatments that offer more than just temporary relief. Our dual-action chewable tablets provide an effective solution by delivering rapid relief and preventing symptom recurrence. We are proud of our R&D team for developing such an innovative formulation," he said.

Designed for Convenience and Efficacy

The new chewable tablets are intended for short-term relief of heartburn and acid regurgitation in adults and adolescents aged 16 and older. The chewable format ensures ease of use and portability, making it an ideal choice for those seeking quick relief, even when they are on the go.

Akums’ commitment to quality, safety, and efficacy is reflected in this launch, reaffirming its position as a leader in the pharmaceutical manufacturing sector. By introducing advanced, patient-centric solutions, Akums aims to cater to the evolving healthcare needs of Indian consumers.

A Step Forward in Pharmaceutical Innovation

This latest product launch underscores Akums’ dedication to delivering world-class healthcare products that not only address current health concerns but also set new standards in pharmaceutical innovation. With a focus on providing effective, high-quality healthcare solutions, Akums continues to expand its product portfolio, strengthening its leadership position in the Indian pharmaceutical market.